Potential risk biomarkers found for schizophrenia resulting from cannabis use
A study by the Neuropsychopharmacology and IBeA groups of the University of the Basque Country (UPV/EHU) paves the way to obtain biomarkers to predict the development of the disorder The UPV/EHU study, recently published in the journal Scientific Reports, has analysed and compared the fatty acids in the blood of individuals with schizophrenia, of those with cannabis use disorder and of those with both diagnoses, with the aim of shedding light on new biomarkers and improving the understanding of the biological relationship between the two disorders. The study also offers a powerful tool for identifying new biomarkers. Cannabis is one of the most widely used substances in the world, with some 228 million users between the ages of 15 and 64. The risk of developing schizophrenia increases significantly with cannabis use, especially when it starts at a young age. What is more,…
